articleStrokeAug 7, 2008BRONZE OA

Clazosentan to Overcome Neurological Ischemia and Infarction Occurring After Subarachnoid Hemorrhage (CONSCIOUS-1)

Goethe University Frankfurt · St. Michael's Hospital · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Methods

Patients (n=413) were randomized to placebo or clazosentan beginning within 56 hours and continued up to 14 days after initiation of treatment. The primary end point was moderate or severe angiographic vasospasm based on centrally read, blinded evaluation of digital subtraction angiography at baseline and 7 to 11 days postsubarachnoid hemorrhage. A morbidity/mortality end point, including all-cause mortality, new cerebral infarct from any cause, delayed ischemic neurological deficit due to vasospasm, or use of rescue therapy, was evaluated by local assessment. Clinical outcome was assessed by the extended Glasgow Outcome Scale at 12 weeks.

Results

Moderate or severe vasospasm was reduced in a dose-dependent fashion from 66% in the placebo group to 23% in the 15 mg/h clazosentan group (risk reduction, 65%; 95% CI, 47% to 78%; P

Citation impact

639
total citations
FWCI
27.02
Percentile
100%
References
39
Citations per year

Authors

9

Topics & keywords

Keywords
  • Medicine
  • Subarachnoid hemorrhage
  • Ischemia
  • Stroke (engine)
  • Infarction
  • Brain ischemia
  • Cardiology
  • Anesthesia
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding